Inotrem's Precision Medicine Strategy Shows Breakthrough Results for Septic Shock Treatment with Nangibotide
核心洞察
Inotrem published breakthrough precision medicine strategy for nangibotide in Intensive Care Medicine, demonstrating significant clinical improvements in septic shock (搜索) patients with elevated sTREM-1 (搜索) biomarker levels.
The study showed statistically significant organ function improvement (p=0.007) and increased shock reversal rates (+22.2%, p=0.006) in biomarker-positive patients who received nangibotide versus placebo.
This mechanism-based approach has regulatory approval from FDA, EMA, and PMDA, representing a new paradigm for drug development in intensive care medicine.
Inotrem, a clinical-stage biotechnology company, has published groundbreaking research in Intensive Care Medicine demonstrating the efficacy of its precision medicine approach for treating septic shock (搜索) with nangibotide, a first-in-class TREM-1 (搜索) inhibitor. The study establishes soluble TREM-1 (sTREM-1 (搜索)) as a crucial biomarker for identifying high-risk patients who benefit most from targeted treatment.
Biomarker-Guided Treatment Shows Significant Clinical Benefits
The research, titled "A mechanism-based prognostic enrichment strategy for the development of the TREM-1 (搜索) inhibitor nangibotide in septic shock (搜索)," confirms that elevated sTREM-1 (搜索) levels identify the most critically ill septic shock patients with severe organ failure (搜索) and highest mortality risk. In this enriched patient population, nangibotide demonstrated statistically significant improvements when added to standard care.
"This is a breakthrough precision medicine approach in septic shock (搜索)," said Dr. Bruno François from Limoges University Hospital, lead author and Coordinating Investigator of the phase 2b clinical program. "Our findings confirm the efficacy of nangibotide in an enriched patient population with elevated levels of the sTREM-1 (搜索) biomarker, thus linking the targeted pathway dysregulation, septic shock severity, and drug mechanism of action."
Strong Clinical Outcomes in Biomarker-Positive Patients
The study revealed that sTREM-1 (搜索) biomarker-positive patients do not respond adequately to current standard care. However, nangibotide administration resulted in clinically meaningful improvements across multiple endpoints. The primary endpoint showed a statistically significant improvement in organ function, measured by change in sequential organ failure (搜索) assessment score from baseline to day 5, with a difference of -2.5 points favoring nangibotide versus placebo (p=0.007).
Additionally, patients receiving nangibotide experienced a 22.2% increase in shock reversal rates compared to placebo (p=0.006). The study also demonstrated shorter intensive care unit stays and improved long-term outcomes, including reduced morbidity and mortality. Importantly, no safety concerns were identified with nangibotide treatment.
Regulatory Alignment and Development Strategy
The precision medicine strategy has gained regulatory support from major health authorities. "With these results, we are entering a new paradigm for drug development in intensive care," stated Sven Zimmermann, CEO of Inotrem. "This prognostic enrichment strategy has been agreed with the 3 main regulatory agencies FDA, EMA, and PMDA and paves the way for the future development of nangibotide."
Nangibotide has received PRIME (PRIority Medicine) designation from the European Medicine Agency and Fast Track designation from the U.S. Food and Drug Administration. The regulatory pathway to registration has been established with FDA, EMA, and PMDA.
Addressing Critical Unmet Medical Need
Septic shock (搜索) represents the most severe complication of sepsis (搜索), caused by an uncontrolled immune response leading to acute organ failure (搜索). The condition affects over 1.1 million people annually in the United States and five main European Union countries, with mortality rates reaching up to 40%. Despite this significant disease burden, management remains limited to symptom control with no causal treatments available, creating substantial unmet medical need.
TREM-1 Pathway as Therapeutic Target
TREM-1 (搜索) functions as an immune amplifier upstream of most known inflammatory pathways and serves as a crucial mediator of immune dysregulation in acute inflammatory diseases, including septic shock (搜索). Nangibotide, as a first-in-class immunomodulatory peptide, selectively inhibits the TREM-1 pathway to restore immune balance and vascular function in life-threatening inflammatory conditions.
The drug has demonstrated a favorable safety profile and consistent efficacy signals in biomarker-defined populations throughout its clinical development program.